- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.08. | AcouSort AB: AcouSort AB - Interim Report for the period January - June 2025 | 51 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.
April - June 2025 for the GroupNet sales amounted to TSEK 1,551 (961)Result before tax amounted... ► Artikel lesen | |
| 28.05. | AcouSort AB: AcouSort AB - Interim Report for the period January - March 2025 | 166 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.
First quarter 2025 for the GroupNet sales amounted to TSEK 1,595 (1,357)Result before tax amounted... ► Artikel lesen | |
| ACOUSORT Aktie jetzt für 0€ handeln | |||||
| 09.04. | AcouSort AB: Bulletin from the Extraordinary General Meeting of AcouSort AB (publ) | 119 | GlobeNewswire (Europe) | The following resolutions were passed at the Extraordinary General Meeting (the "EGM") of AcouSort AB (publ) (the "Company") on 9 April 2025 in Lund.
Rights issue of sharesThe EGM resolved to approve... ► Artikel lesen | |
| 09.04. | XFRA CAPITAL ADJUSTMENT INFORMATION - 09.04.2025 | 184 | Xetra Newsboard | Das Instrument N7S CA87043J2039 SWEET POISON SPIRITS INC. EQUITY wird cum Kapitalmassnahme gehandelt am 09.04.2025 und ex Kapitalmassnahme am 10.04.2025 The instrument N7S CA87043J2039 SWEET POISON... ► Artikel lesen | |
| 26.03. | AcouSort AB: AcouSort's CEO answers questions about the company's rights issue and gives his view on the future | 199 | GlobeNewswire (Europe) | In connection with AcouSort's announcement of its plan to carry out a rights issue, several shareholders have contacted the company with questions regarding both the issue itself and how the management... ► Artikel lesen | |
| 19.03. | AcouSort AB: AcouSort in new collaboration to improve sepsis treatment | 217 | GlobeNewswire (Europe) | AcouSort's business strategy relies on early development collaborations to integrate its separation technology in partnering companies' products and systems. The most recent collaboration of this kind... ► Artikel lesen | |
| 03.03. | AcouSort AB: AcouSort and Bio-ReCell enter collaboration | 177 | GlobeNewswire (Europe) | AcouSort AB ("AcouSort") and Bio-ReCell Ltd ("Bio-ReCell") announce that the two companies have signed a Letter of Intent to jointly explore developing a system for automated clean-up and isolation... ► Artikel lesen | |
| 14.02. | AcouSort AB: Year end report for AcouSort AB 1 January - 31 December 2024 | 93 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037
Fourth quarter for the GroupNet sales amounted to TSEK 1,221 (0)Result before tax amounted to... ► Artikel lesen | |
| 27.11.24 | AcouSort AB: AcouSort AB - Interim Report for the period July - September 2024 | 138 | GlobeNewswire (Europe) | Summary of the interim report
Significant events during the third quarterOn July 12, AcouSort announces that the Company and GenSensor will collaborate to combine AcouSort's acoustofluidics technology... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 53,02 | -0,45 % | Novonesis (Novozymes A/S): Novonesis and Novo Nordisk will explore new solutions to improve metabolic health | Novonesis and Novo Nordisk join forces in a new research collaboration to explore solutions that seek to preserve and optimize metabolic health and well-being for people. COPENHAGEN, Denmark... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 6,682 | +2,27 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
| SARTORIUS STEDIM BIOTECH | 185,70 | +5,63 % | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| CRESCENT BIOPHARMA | 13,050 | +2,19 % | Crescent Biopharma Reports Second Quarter 2025 Financial Results and Recent Business Highlights | Completed Merger with GlycoMimetics and Previously Announced $200 Million Private Financing Supporting Pipeline of Next Generation Therapeutics for Solid Tumors Recent Leadership Appointments Bring... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,030 | +2,95 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| BIOLIFE SOLUTIONS | 22,000 | +1,85 % | BioLife Solutions, Inc.: BioLife Solutions Reports Second Quarter 2025 Financial Results | Cell Processing revenue of $23.0 million, up 28% over Q2 2024
GAAP gross margin of 62% and non-GAAP adjusted gross margin of 65%
GAAP net loss of $15.8 million... ► Artikel lesen | |
| QIAGEN | 38,905 | +1,16 % | QIAGEN N.V.: QIAGEN erhält europäische CE-IVDR-Zertifizierung für das gesamte QIAstat-Dx-Portfolio | Komplettes Portfolio an QIAstat-Dx-Panels ab jetzt CE-IVDR-zertifiziert und damit für den Einsatz in der klinischen syndromischen Testung zugelassen ein klares Bekenntnis zu Diagnostik auf höchstem... ► Artikel lesen | |
| 89BIO | 14,965 | +85,21 % | Milliarden-Pharma-Übernahme: Roche kauft sich in Biotech-Milliardenmarkt ein - 89bio im Fokus | © Foto: SOPA Images - Sipa USARoche kauft das US-amerikanische Biotech-Unternehmen 89bio für bis zu 3,5 Milliarden US-Dollar. Im Fokus steht ein Hoffnungsträger gegen die Fettleberkrankheit MASH, ein... ► Artikel lesen | |
| EVOTEC | 6,292 | +1,26 % | EQS-NVR: Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Evotec SE
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem... ► Artikel lesen | |
| BIONTECH | 81,60 | -1,75 % | Community-Rückblick: BNTX Rally nur von kurzer Dauer: "Die Top-Meldung ist zu nem Non-Event geworden" | BioNTech konnte einen Durchbruch nach der Phase-3-Studie zum Brustkrebspräparat "Trastuzumab Pamirtecan" vermelden. Diese Nachricht trieb die Aktie zweistellig nach oben. Die Rally war allerdings nur... ► Artikel lesen | |
| VIKING THERAPEUTICS | 21,370 | +9,41 % | AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play? | ||
| RECURSION PHARMACEUTICALS | 4,910 | +4,03 % | What Analysts Are Saying About Recursion Pharmaceuticals Stock | ||
| SUMMIT THERAPEUTICS | 18,790 | +3,87 % | Summit Therapeutics stock rating reiterated at Buy by H.C. Wainwright | ||
| MINERALYS THERAPEUTICS | 40,270 | +7,99 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen | |
| OCUGEN | 1,151 | +2,72 % | Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea | Upfront fees and near-term development milestone payments totaling up to $7.5 millionPotential sales milestones of $180 million or more in first 10 years of commercializationRoyalties equaling 25%... ► Artikel lesen |
ACOUSORT AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,230 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACOUSORT AB finden Sie auf Wallstreet Online.